Cargando…
Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019
BACKGROUND: Uptake of coronavirus disease 2019 (COVID-19) bivalent vaccines and the oral medication nirmatrelvir-ritonavir (Paxlovid) has remained low across the United States. Assessing the public health impact of increasing uptake of these interventions in key risk groups can guide further public...
Autores principales: | Park, Hailey J, Tan, Sophia T, León, Tomás M, Jain, Seema, Schechter, Robert, Lo, Nathan C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478155/ https://www.ncbi.nlm.nih.gov/pubmed/37674629 http://dx.doi.org/10.1093/ofid/ofad415 |
Ejemplares similares
-
Predicting the public health impact of bivalent vaccines and nirmatrelvir-ritonavir against COVID-19
por: Park, Hailey J., et al.
Publicado: (2023) -
2374. Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir against COVID-19
por: Park, Hailey J, et al.
Publicado: (2023) -
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
por: Savinkina, Alexandra, et al.
Publicado: (2022) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)